Gensenoside Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells

Cellular Physiology and Biochemistry

Volumn 26, Issue 6, 2010, Pages 849-858

  Chen, Qing Jiang ^a   Zhang, Ming Zhi ^a   Wang, Le Xin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Cancer; Ginsenoside Rg3; Hypoxia; VEGF

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLOOXYGENASE 2; GINSENOSIDE RG 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL ASSAY; CELL HYPOXIA; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ESOPHAGUS CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 78651228186     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323994     Document Type: Article

References (44)

1. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004;9:259-274.
2. Liu WK, Xu SX, Che CT: Anti-proliferative effect of ginseng saponins on human prostate cancer cell line. Life Sci 2000;67:1297-1306.
3. Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, Song HB, Yi C: Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 2009;9:250.
4. Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su MM, Wang DD, Wang WJ: Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl) 2008;121:1394-1397.
5. Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW, Hong JT: Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 2009;32:755-765.
6. Sullivan R, Graham CH: Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 2007;26:319-331.
7. Kesisis G, Broxterman H, Giaccone G: Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 2007;13:2795-2809.
8. Argyriou AA, Giannopoulou E, Kalofonos HP: Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 2009;77:1-11.
9. Zhang Q, Kang X, Yang B, Wang J, Yang F: Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice. Cancer Biother Radiopharm 2008;23:647-653.
10. Brahimi-Horn MC, Chiche J, Pouysségur J: Hypoxia and cancer. J Mol Med 2007;85:1301-1307.
11. Fong GH: Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 2008;11:121-140.
12. Rasheed S, McDonald PJ, Northover JM, Guenther T: Angiogenesis and hypoxic factors in colorectal cancer. Pathol Res Pract 2008;204:501-510.
13. Gort EH, Groot AJ, Van Der Wall E, Van Diest PJ, Vooijs MA: Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 2008;8:60-67.
14. Onnis B, Rapisarda A, Melillo G: Development of HIF-1 Inhibitors for Cancer Therapy. J Cell Mol Med 2009;13:2780-2786.
15. Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000;19:19-27.
16. Liao Z, Mason KA, Milas L: Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 2007;67:821-845.
17. Toomey DP, Murphy JF, Conlon KC: COX-2, VEGF and tumour angiogenesis. Surgeon 2009;7:174-180.
18. Quivy V, Van Lint C: Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 2004;68:1221-1229.
19. Cortés Sempere M, Rodríguez Fanjul V, Sánchez Pérez I, Perona R: The role of the NFkappaB signalling pathway in cancer. Clin Transl Oncol 2008;10:143-147.
20. Chen F, Beezhold K, Castranova V: Tumor promoting or tumor suppressing of NF-kappa B, a matter of cell context dependency. Int Rev Immunol 2008;27:183-204.
21. Tabruyn SP, Griffioen AW: NF-kappa B: a new player in angiostatic therapy. Angiogenesis 2008;11:101-106.
22. Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, Fang JY: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008;10:287-297.
23. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H: Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367-3377.
24. Shemirani B, Crowe DL: Hypoxic induction of HIF-1alpha and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 2002;38:251-257.
25. Yao H, Wang H, Zhang Z, Jiang BH, Luo J, Shi X: Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 2008;123:1255-1261.
26. Lee MY, Joung YH, Lim EJ, Park JH, Ye SK, Park T, Zhang Z, Park DK, Lee KJ, Yang YM: Phosphorylation and activation of STAT proteins by hypoxia in breast cancer cells. Breast 2006;15:187-195.
27. Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator-Schmitt M, Fusenig NE, Angel P, Schorpp-Kistner M: Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 2007;26:710-719.
28. Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007;26:281-290.
29. Pradeep CR, Sunila ES, Kuttan G: Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther 2005;4:315-21.
30. Breen E, Tang K, Olfert M, Knapp A, Wagner P: Skeletal muscle capillarity during hypoxia: VEGF and its activation. High Alt Med Biol 2008;9:158-166.
31. Chen L, Shibasaki F: Angiogenesis and metastasis of carcinoma. Clin Calcium 2006;16:613-19.
32. Wang W, Xu GL, Jia WD, Wang ZH, Li JS, Ma JL, Ge YS, Xie SX, Yu JH: Expression and correlation of hypoxia-induc-ible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res 2009;37:417-25.
33. Maynard MA, Ohh M: Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004;24:1-13. (Pubitemid 38250481)
34. Baek JH, Liu YV, McDonald KR, Wesley JB, Hubbi ME, Byun H, Semenza GL: Spermidine/spermine-N1-acetyl-transferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1alpha. J Biol Chem 2007;282:23572-80.
35. Baek JH, Liu Y V, McDonald KR, Wesley JB, Hubbi ME, Byun H, Semenza GL: Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells. Gynecol Oncol 2004;94:422-426.
36. Huang SP, Wu MS, Shun CT, Wang HP, Hsieh CY, Kuo ML, Lin JT: Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 2005;12:229-241.
37. Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008;18:19-26.
38. Karin M: How NF-κB is activated: the role of the IkB kinase (IKK) complex. Oncogene 1999;18:6867-6874.
39. Hu MC, Hung MC: Role of IkappaB kinase in tumorigenesis. Future Oncol 2005;1:67-78.
40. Tian F, Zang WD, Hou WH, Liu HT, Xue LX: Nuclear factor-κB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta Biochim Biophys Sin (Shanghai) 2006;38:318-326.
41. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-732.
42. Jung JY, Isaacs JS, Lee S, Trepel J, Neckers L: IL-1(3 mediated up-regulation of HIF-1 a via an NFKB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17:2115-2117.
43. Wan J, Ma J, Mei J, Shan G: The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res 2009;28:150.
44. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK, Chung MH: STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 2005;19:1296-1298.